Loading
A single-centre review of recurrent ovarian cancer reported longer time before progression on a circulating tumour cell-guided treatment line than on each patient's previous line. The comparison was not randomised and cannot show that the assay caused the difference.
Investigators reviewed 334 records from one centre. Eighty-eight patients were referred for circulating tumour cell testing, 66 received treatment described as guided by the result, and 48 completed treatment and response assessment. Median progression-free survival was 6.67 months on the guided line versus 4.40 months on each patient's preceding line; 27 of 48 had a progression-free survival ratio above 1.3.
This was a retrospective, non-randomised comparison, not a trial against contemporary guideline-based treatment. Patients who did not receive the suggested treatment often lacked access or coverage, creating important selection and socioeconomic differences. Overall survival from diagnosis did not differ significantly between guided and non-guided groups. RGCC supported administrative data collection, and one author worked for its Israeli representative.
The study is a hypothesis-generating signal that justifies a prospective controlled trial. It does not establish that an RGCC assay improves survival or that its recommendations outperform standard oncology care.
Shares RGCC International, Circulating tumour cell capture, Functional (ex vivo) drug testing, Liquid biopsy (ctDNA) and the tags rgcc, retrospective.
Shares RGCC International, Circulating tumour cell capture, Liquid biopsy (ctDNA).
Shares Circulating tumour cell capture, Functional (ex vivo) drug testing.
Shares RGCC International and the tag rgcc.
Shares Circulating tumour cell capture, Liquid biopsy (ctDNA).
Shares Circulating tumour cell capture, Liquid biopsy (ctDNA).
Shares Circulating tumour cell capture, Liquid biopsy (ctDNA), Ovarian cancer.
Shares Circulating tumour cell capture, Functional (ex vivo) drug testing, Liquid biopsy (ctDNA), Ovarian cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/